Baxter International Inc (BAX) Releases Earnings Results, Beats Expectations By $0.07 EPS

Baxter International Inc (BAX) reported quarterly earnings results on Tuesday, Apr-26-2016. The company said it had a profit of $0.36 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $0.29. The company posted revenue of $2375.00 million in the period, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Many Wall Street Analysts have commented on Baxter International Inc. Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016. Company shares were Reiterated by RBC Capital Mkts on Feb 3, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 40 from a previous price target of $37 .

Baxter International Inc opened for trading at $43.1 and hit $43.59 on the upside on Friday, eventually ending the session at $43.32, with a gain of 0.72% or 0.31 points. The heightened volatility saw the trading volume jump to 3,33,86,654 shares. Company has a market cap of $23,734 M.

In a different news, on Apr 6, 2016, John D Forsyth (director) sold 1,887 shares at $41.75 per share price. According to the SEC, on Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price. On Mar 15, 2016, James R Iii Gavin (director) sold 5,660 shares at $40.34 per share price, according to the Form-4 filing with the securities and exchange commission.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Baxter International Inc

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.